A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes

• Status: Completed
• Trial end date: 2019-05-06
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this early feasibility study is to assess the predictive low glucose suspend (PLGS) feature's safety, functionality and performance.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Insulin; Insulin Lispro; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Participants with T1DM for at least 2 years and who have used an insulin delivery system with any rapid-acting insulin analog for the preceding 6 months

• Have a body mass index of 18.5 to 37 kilogram per meter squared

• Have a hemoglobin A1c level ≥6.0% and ≤9.0%

Exclusion Criteria:

• Have known allergies or history of hypersensitivity to insulin lispro

• Have had an episode of severe hypoglycemia within the past 6 months

• Have had more than 1 episode of diabetic ketoacidosis in the past 6 months